FREE TREATMENT REPORT

See ratings and reviews when you sign up for an account.

A Post-marketing Surveillance to Monitor the Safety of AVAMYS? NS Administered in Korean Subjects According to the Prescription Information

This study is currently Recruiting

May 2011 By GlaxoSmithKline

First Recieved on October 22, 2009

Last Updated on May 12, 2011

Sponsor: GlaxoSmithKline
Collaborators:
Information provided by: GlaxoSmithKline
Identifier: NCT01001130

Purpose

An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of fluticasone furoate nasal spray administered in Korean subjects according to the prescribing information

Study Type: Observational
Study Design: Observational Model: Case-Only, Time Perspective: Prospective

Eligibility

Ages Eligible for Study:2 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No
Criteria

Inclusion Criteria: - Subjects with seasonal allergic rhinitis or perennial allergic rhinitis aged 2 years and older. - Subjects with no experience of treatment using fluticasone furoate nasal spray - Subjects who are contactable over the phone - Subjects who can follow the prescription Exclusion Criteria: - Subjects with known hypersensitivity to fluticasone furoate or any excipients in the product - Subjects with recent nasal septal surgery or nasal septal perforation

Investigators

  • Investigator: GSK Clinical Trials - Study Director - GlaxoSmithKline

Locations

  • GSK Investigational Site

    Seongnam-si Gyeonggi-do, 463-707 Korea, Republic of

advertisement
V2012.311.925.327
Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.